Objective To investigate human eididymis protein 4 levels in transitional cell carcinoma of the urinary system and its relationship with clinicopathological features. Methods 45 patients with TCC, 20 with benign urinary diseases, and 10 healthy controls were included in the study, we investgate the clinicopathological features of the TCCand the preopreation HE4 level was compared with postoperation. Results The HE4 levels were significantly higher in pati-aents with TCC compared to patients with benign urinary diseases patients (P<0. 05) and healthy controls (P< 0. 05) ,There was a significant difference between HE4 levels in patients before and after operation(P<0. 05) , However there was no differences between HE4 levels based on clinicopathological features(P>0. 05). The sensitivity and specificity of HE4 at a cutoff value of 76. 1 pmol/1 were 80. 0% and 75. 0% ,respectively. Conclusion HE4 may be used as a tumor biomarker for the TCCand may become a tool to assess the prognosis of TCC.%目的 检测人附睾蛋白4(HE4)在移行细胞癌中的水平,推测其与移行细胞癌肿瘤学特征的关联性.方法 我们选择45例移行细胞癌患者,20例良性泌尿系统疾病患者,10例健康者.观察病人的年龄、性别、体重指数及肿瘤的分级、分期等基本临床资料,分析泌尿系统移行细胞癌病人手术前、后血清人附睾蛋白4的水平变化.结果 移行细胞癌的HE4水平明显高于良性肿瘤组及健康对照组,差异有统计学意义(P<0.05),非肌层浸润性移行细胞癌的HE4水平明显高于泌尿系统良性疾病及健康者,差异有统计学意义(P<0.05).手术前、后的HE4水平相比较有明显差异(P<0.05).HE4水平与年龄、性别、肿瘤位置、数目,临床分期及分级关系不大,差异无统计学意义.结论 人附睾蛋白4(HE4)可作为泌尿系统移行细胞癌筛查的肿瘤标志物.
展开▼
